BioSpace News Archive

Gelesis Holdings, Inc. today reported financial results for the year ended December 31, 2022.

Silence Therapeutics plc today announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development.

Radiopharm Theranostics is pleased to announce that the Company will participate in Jefferies Inaugural Radiopharma Innovation Summit being held in New York City on April 3rd, 2023.

Zynerba Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided an overview of recent operational highlights and a pipeline update.

Vera Therapeutics, Inc. today reported its business highlights for the fourth quarter and financial results for the full year ended December 31, 2022.

HMNC Brain Health together with Develco Pharma, announced that the last patient has been randomized in its proof-of-concept Phase II clinical trial of ‘Ketabon’, an oral prolonged-release ketamine formulation for Treatment-Resistant Depression.

Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant’s ADAR1 program.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”) today announced the publication of an expansive post-marketing data analysis demonstrating high response and remission rates for depression and anxious depression patients undergoing Deep Transcranial Magnetic Stimulation (Deep TMS™) treatment.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO) today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”) has demonstrated the utility of a human in vitro model of iPSC-derived excitatory neurons for a better understanding of which forms of amyloid beta oligomers contribute to the pathogenesis of AD in the human brain.